Free Supply Chain and Inventory Management Certificate Exam Practice Questions

Sample Practice Questions

Try these 10 sample questions from the Supply Chain and Inventory Management Certificate Exam practice bank. Each includes the answer and explanation. Continue with the interactive practice above to review the full question set.

1. 1What comparison is part of FDA's scientific evaluation of a new drug?

   1. A. Its retail price versus the pharmacy's acquisition cost
   2. B. Its expected benefits versus its known risks
   3. C. Its market share versus competing manufacturers
   4. D. Its wholesaler discounts versus dispensing fees

   Answer: B

   Explanation: FDA asks, "Do the benefits of this drug outweigh the risks?" This is a benefit–risk assessment rather than a profitability assessment.

   Reference: How the FDA Regulates and Approves Drugs — Page 1, questions reviewed by FDA scientists

2. 2What is the minimum DSCSA retention period for applicable transaction tracing records maintained by a dispenser after a transaction?

   1. A. Two years
   2. B. Three years
   3. C. Five years
   4. D. Six years

   Answer: D

   Explanation: Section 582(d)(1)(A)(iii) requires the dispenser to "maintain such information, history, and statements for not less than 6 years after the transaction." The minimum is six years; this differs from the DEA two-year controlled-record minimum.

   Reference: Title II of the Drug Quality and Security Act — Section 582(d)(1)(A)(iii)

3. 3An entity holds the approved drug application for a product but contracts out physical production. Under the DSCSA manufacturer definition, how is the application holder classified?

   1. A. Only a third-party logistics provider
   2. B. Only a returns processor
   3. C. A manufacturer
   4. D. Only a dispensing pharmacy

   Answer: C

   Explanation: The manufacturer definition includes "a person that holds an application approved under section 505 or a license issued under section 351 of the Public Health Service Act for such product, or if such product is not the subject of an approved application or license, the person who manufactured the product;" Holding the approved product application satisfies this branch even when physical production is contracted out.

   Reference: Title II of the Drug Quality and Security Act — Definitions — Manufacturer — approved-application holder

4. 4Which statement describes FDA oversight after an approved drug enters routine patient use?

   1. A. Monitoring transfers entirely to individual state pharmacy boards.
   2. B. Approval ends routine federal evaluation of the drug's safety.
   3. C. Monitoring resumes only when the manufacturer seeks a new indication.
   4. D. FDA continues monitoring the drug's safety and effectiveness.

   Answer: D

   Explanation: The source states, "the FDA continues to monitor their safety and effectiveness." Approval does not end FDA surveillance.

   Reference: How the FDA Regulates and Approves Drugs — Page 2, What is the FDA’s Role After Drugs are Approved?

5. 5A pharmacy hires an authorized wholesaler to maintain its DSCSA tracing records under a written agreement. What remains the pharmacy's responsibility?

   1. A. Retain the agreement and remain responsible for its dispenser obligations.
   2. B. Transfer all legal responsibility to the wholesaler by paying its fee.
   3. C. Discard its agreement once the wholesaler stores the first transaction.
   4. D. Maintain records only when the wholesaler cannot retrieve them.

   Answer: A

   Explanation: The statute states, "If a dispenser enters into such an agreement, the dispenser shall maintain a copy of the written agreement and shall not be relieved of the obligations of the dispenser under this subsection." The pharmacy retains the agreement and its legal responsibilities even when a wholesaler stores the data.

   Reference: Title II of the Drug Quality and Security Act — Section 582(d)(1)(B), Agreements with third parties

6. 6An establishment repacks and relabels a product for further sale. Which DSCSA supply-chain role describes it?

   1. A. Repackager
   2. B. Dispenser
   3. C. Third-party logistics provider
   4. D. Returns processor

   Answer: A

   Explanation: Section 581(16) describes an establishment that "repacks and relabels a" product or package for further sale or distribution. This involves modifying the marketed packaging, not merely storing it.

   Reference: Title II of the Drug Quality and Security Act — Section 581(16), Repackager

7. 7Why does FDA conduct ongoing inspections of facilities that manufacture drugs?

   1. A. To check whether manufacturers follow safety and quality standards
   2. B. To negotiate the pharmacy's annual purchasing commitments
   3. C. To determine which prescriptions a pharmacy should refill
   4. D. To assign a standard retail selling price to each medicine

   Answer: A

   Explanation: Inspections serve "to ensure manufacturers are following safety and quality standards." This addresses manufacturing quality rather than purchasing or prescribing decisions.

   Reference: How the FDA Regulates and Approves Drugs — Page 2, What is the FDA’s Role After Drugs are Approved?

8. 8A dispenser concludes a suspect-product investigation on March 1, 2026. Under the statutory minimum, when does its six-year investigation-record retention period run from?

   1. A. The product's manufacture date
   2. B. The original wholesaler invoice date
   3. C. The conclusion of the investigation
   4. D. The date of the pharmacy's next inspection

   Answer: C

   Explanation: Section 582(d)(4)(A)(iv) states "years after the conclusion of the investigation." The relevant trigger is investigation completion rather than the underlying transaction date.

   Reference: Title II of the Drug Quality and Security Act — Section 582(d)(4)(A)(iv), Records

9. 9A business purchases finished prescription drugs from unrelated manufacturers and resells them in unopened original packaging to unrelated pharmacies for dispensing. These are its sole drug-supply activities, and no statutory distribution exclusion applies. Which DSCSA role describes it?

   1. A. Dispenser
   2. B. Manufacturer
   3. C. Returns processor
   4. D. Wholesale distributor

   Answer: D

   Explanation: Section 581(29) defines a wholesale distributor as a person "engaged in wholesale distribution". Section 503(e)(4) describes "the distribution of a drug subject to subsection (b) to a person other than a consumer or patient". The business takes ownership and resells finished drugs to pharmacies rather than patients. Its stated activities involve neither manufacture, dispensing nor returns processing, and the stem excludes statutory distribution exceptions.

   Reference: Title II of the Drug Quality and Security Act — Section 581(29), Wholesale distributor

10. 10New postmarketing safety data identify a risk that patients should know about. Which response is within FDA's described role?

    1. A. Assigning each patient a different insurance formulary
    2. B. Negotiating a uniform rebate for every affected product
    3. C. Recommending that the manufacturer add a labeling warning
    4. D. Replacing each prescriber's individual treatment assessment

    Answer: C

    Explanation: FDA says, "The FDA can recommend a drug maker update the drug labeling by adding warnings or updating dosage information." Updating a warning follows that role.

    Reference: How the FDA Regulates and Approves Drugs — Page 2, What is the FDA’s Role After Drugs are Approved?